Description de l'entreprise
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. It develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. They invented proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dan Hicklin |
| Conseil d'administration |
| Tim Trost, Randi Isaacs, Chulani Karunatilake, Ellen Lubman, Cynthia Seidel-Dugan |
| Conseil de surveillance |
| Luke Evnin, Michael Atkins, Meeta Chatterjee, Derek DiRocco, Dan Hicklin, Alon Lazarus, Briggs W. Morrison, Mike Sherman |
Données de l'entreprise
| Nom: |
Werewolf Therapeutics Inc |
| Adresse: |
200 Talcott Avenue, 2nd Floor,Watertown, MA 02472 |
| Téléphone: |
+1 617-952-0555 |
| Fax: |
- |
| Courriel: |
info@werewolftx.com
|
| Internet: |
https://werewolftx.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
- |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
29/04/2021 |
Relations avec les investisseurs
| Nom: |
Josh Rappaport |
| Téléphone IR: |
+1 212-362-1200 |
| IR-Fax: |
- |
| E-mail IR: |
IR@werewolftx.com
|
